TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.

被引：96

作者：

Konstantinopoulos, Panagiotis A.

Waggoner, Steven E.

Vidal, Gregory A.

Mita, Monica M.

Fleming, Gini F.

Holloway, Robert W.

Van Le, Linda

Sachdev, Jasgit C.

Chapman-Davis, Eloise

Colon-Otero, Gerardo

Penson, Richard T.

Matulonis, Ursula A.

Kim, Young B.

Moore, Kathleen N.

Swisher, Elizabeth M.

Dezube, Bruce Jeffrey

Wang, Jing Y.

Buerstatte, Nathan

Arora, Sujata

Munster, Pamela N.

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[2] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Cleveland, OH 44106 USA

[3] West Clin, Memphis, TN USA

[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Florida Hosp Gynecol Oncol, Florida Hosp Canc Inst, Orlando, FL USA

[7] Florida Hosp Gynecol Oncol, Global Robot Inst, Orlando, FL USA

[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[9] Virginia G Piper Canc Ctr Clin Trials, HonorHlth Res Inst, Scottsdale, AZ USA

[10] Virginia G Piper Canc Ctr Clin Trials, Translat Genom Res Inst, Scottsdale, AZ USA

[11] Cornell Univ, Weill Cornell Med, New York, NY 10021 USA

[12] Mayo Clin, Jacksonville, FL 32224 USA

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] Tufts Med Ctr, Boston, MA USA

[15] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[16] Sarah Cannon Res Inst, Nashville, TN USA

[17] Univ Washington, Seattle, WA 98195 USA

[18] TESARO Inc, Waltham, MA USA

[19] UCSF Med Ctr Mt Zion, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

106

引用

页数：1